JCB, Volume 25, Number 3, 2020 Commentary Vol.25 No. 3 (2020) Could COVID-19 Cause ‘Biopharming’ to Bloom? Kathleen Hefferon At an accelerated rate in response to the COVID-19 pandemic, academic and corporate scientists are using genetic engineering techniques to reprogram plants to produce significant concentr Abstract Download PDF Articles Vol.25 No. 3 (2020) A critical review on nano-food packaging and its applications. Sheelendra M BHATT The present manuscript addresses the effect of nanotechnology in various food sectors. Increasedfood functionality, enhanced flavor, reduced delivery of food additives are some of the Abstract Download PDF Articles Vol.25 No. 3 (2020) Biopharma licensing and M&A trends in the 21st-century landscape Rahul Khetan The declining in-house R&D productivity has compelled the biopharmaceutical firms to supplement their innovation pipelines with well-managed licensing or acquisition deals. The relian Abstract Download PDF Articles Vol.25 No. 3 (2020) COVID-19 Diagnostic Testing: Lessons Learned for Innovative Product Development During A Public Health Emergency Christopher Lamb In response to the Coronavirus Disease-2019 (COVID-19) pandemic, the U.S. Food and Drug Administration (FDA) used its emergency authority through Emergency Use Authorizations (EUAs) to ma Abstract Download PDF From the Boardroom Vol.25 No. 3 (2020) The Spreading Cancer of Counterfeit Drugs Peter Pitts Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines – with their high-speed “host” being the digitization of patient care. The fut Abstract Download PDF
